|Mr. Paolo Pucci||Chief Exec. Officer and Director||753.33k||173.55k||56|
|Mr. Peter S. Lawrence J.D.||Pres, Chief Operating Officer, Gen. Counsel and Sec.||607.43k||N/A||54|
|Mr. Robert J. Weiskopf||Chief Financial Officer and Treasurer||406.42k||N/A||66|
|Dr. Brian Schwartz M.D.||Chief Medical Officer and Sr. VP of Clinical & Regulatory Affairs||585.74k||N/A||55|
|Dawn Schottlandt CFA||Sr. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. Its lead product candidate is tivantinib (ARQ 197), a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer. The companys clinical-stage products include ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and in Phase Ib for multiple oncology indications; ARQ 092, an inhibitor of the AKT serine/threonine kinase in Phase I clinical trials for multiple oncology indications; ARQ 751, a next-generation inhibitor of AKT in Phase I clinical trial for solid tumors; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell death. Its pre-clinical development program also includes ARQ 531, an inhibitor of Brutons tyrosine kinase. The company has co-development and co-commercialization agreement with Daiichi Sankyo Co., Ltd.; license agreement with Kyowa Hakko Kirin Co., Ltd.; and collaborative research and development agreement with Beryllium Development Corp. Arqule, Inc. was founded in 1993 and is headquartered in Burlington, Massachusetts.
ArQule, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.